The purpose of this study is to evaluate the efficacy and safety of Flamboyant 200/12 association in adults with asthma.

Inclusion Criteria:

• Ability to confirm voluntary participation and agree to all trial purposes by signing and dating the informed consent forms;
• Participants aged 18 years or more;
• Diagnosis of uncontrolled severe asthma;
• Participants with Forced expiratory volume in 1 second (FEV1) > 60% of predicted;

Exclusion Criteria:

• Any clinical and laboratory findings that, in the judgment of the investigator, may interfere with the safety of research participants;
• Known hypersensitivity to the formula components used during the clinical trial;
• History of alcohol and/or substance abuse within 12 months prior to Screening Visit.
• Current smoking or smoking history equivalent to "10 pack years"
• Participants with untreated oral candidiasis;
• Pulmonary disease history (e.g., chronic obstructive pulmonary disease [COPD], cystic fibrosis, bronchiectasis, tuberculosis);
• Participants with a history of acute asthma exacerbation, respiratory tract infection or hospitalization for asthma in the last 4 weeks;
• Known HIV-positive status or active hepatitis B or C virus test result
• Participants with current evidence or history of uncontrolled coronary artery disease, congestive heart failure, myocardial infarction or cardiac arrhythmia;
• Participants with a current medical history of cancer and/or cancer treatment in the last 5 years;
• Participants using medications that would have an effect on bronchospasm and / or lung function.

Double-blind and double-dummy